Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.29 Insider Own23.24% Shs Outstand2.25M Perf Week11.76%
Market Cap5.56M Forward P/E- EPS next Y- Insider Trans1.95% Shs Float1.73M Perf Month16.51%
Income-5.69M PEG- EPS next Q- Inst Own5.08% Short Float0.84% Perf Quarter6.01%
Sales0.00M P/S- EPS this Y- Inst Trans-72.81% Short Ratio0.37 Perf Half Y-1.40%
Book/sh0.63 P/B3.90 EPS next Y- ROA-94.34% Short Interest0.01M Perf Year-72.56%
Cash/sh2.27 P/C1.09 EPS next 5Y- ROE-100.34% 52W Range1.58 - 9.60 Perf YTD5.11%
Dividend Est.- P/FCF- EPS past 5Y-17.26% ROI-115.50% 52W High-74.27% Beta-0.32
Dividend TTM- Quick Ratio16.54 Sales past 5Y0.00% Gross Margin- 52W Low56.33% ATR (14)0.27
Dividend Ex-Date- Current Ratio16.54 EPS Y/Y TTM27.19% Oper. Margin0.00% RSI (14)52.54 Volatility13.80% 11.33%
Employees4 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q44.70% Payout- Rel Volume0.00 Prev Close2.47
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume38.62K Price2.47
SMA201.33% SMA509.98% SMA200-22.95% Trades Volume0 Change0.00%
Feb-27-24 08:30AM
Feb-26-24 08:30AM
Jan-29-24 08:30AM
Nov-13-23 08:30AM
Oct-16-23 08:30AM
08:30AM Loading…
Oct-09-23 08:30AM
Sep-26-23 08:30AM
Sep-20-23 08:30AM
Jul-20-23 04:05PM
Jul-18-23 08:00AM
Jul-17-23 08:30AM
Jun-23-23 08:30AM
Jun-07-23 08:30AM
Jun-05-23 09:41AM
Jun-02-23 12:30PM
08:30AM Loading…
May-30-23 08:30AM
Apr-24-23 08:30AM
Apr-04-23 08:30AM
Feb-14-23 01:50PM
Feb-08-23 05:26AM
Feb-07-23 12:58PM
Dec-05-22 08:30AM
Nov-30-22 08:05AM
Oct-13-22 08:30AM
Jun-21-22 08:30AM
Jun-15-22 08:30AM
Apr-14-22 06:45PM
Apr-13-22 10:54AM
10:00AM Loading…
Apr-12-22 03:20PM
Mar-22-22 08:30AM
Mar-16-22 08:30AM
Jan-12-22 08:30AM
Jan-05-22 09:18AM
Nov-22-21 09:25AM
Oct-20-21 09:25AM
Oct-13-21 09:25AM
Sep-24-21 09:31AM
Aug-17-21 11:02AM
Aug-03-21 09:25AM
Jul-22-21 09:25AM
Jul-13-21 09:25AM
Jul-07-21 09:35AM
Jun-26-21 05:45AM
Jun-03-21 08:22AM
Jun-02-21 09:35AM
May-18-21 05:30PM
May-12-21 09:35AM
May-04-21 04:30PM
Apr-28-21 09:35AM
Apr-13-21 09:35AM
Mar-17-21 09:35AM
Mar-03-21 09:35AM
Mar-02-21 06:38PM
Mar-01-21 08:45AM
Feb-26-21 11:58AM
Feb-25-21 02:37AM
Jan-19-21 09:35AM
Dec-01-20 03:28PM
Nov-30-20 03:52PM
Nov-25-20 08:30AM
Aug-18-20 09:35AM
Jul-21-20 09:35AM
Apr-30-20 10:30AM
Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company. It engages in the business of utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in Pasadena, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van der Baan Bastiaan JeroenPresident and CEOOct 03Buy2.8010,00028,00011,000Oct 05 08:36 PM